Table 2 Clinical and biological characteristics of human subjects investigated for detection of plasma BART miRNAs
Patient code | Age-sex- Country of origin | Tumor histological type (1) | Clinical Staging (2) | EBV status | Plasma viral DNA load (copies/ml) (3) | Ebv-miR-BART 7-3p 2 -ΔCt X1000 | ||
|---|---|---|---|---|---|---|---|---|
EBER detection on tumor sections (3) | EBV serology Positive if > 0.2 Negative if < 0.1 (3) | |||||||
NPC PATIENTS | EXO 14 | 52-M-Vietnam | Non-keratinizing Undifferentiated | T3N3M1 | EBER+ | Not tested | 4202 | 250,5 |
EXO 22 | 51-M-France | Non-keratinizing undifferentiated | T3N2M1 | EBER + | Not tested | 1142 | 2360,3 | |
HEP 1 | 45-M-Cambodia | Non-keratinizing undifferentiated | T1N2M0 | EBER + | Not tested | < 200 | 6 | |
EXO 32 | 40-F-Madagascar | Non-keratinizing undifferentiated | T3N2M0 | EBER+ | Not tested | < 200 | 329,9 | |
HEP 2 | 58-M-France | Non-keratinizing undifferntiated | T3N1M0 | EBER+ | Not tested | 1589 | 502,1 | |
NON-NPC TUMOR CARRIERS | HEP 5 | 69-M- France | Adenocarcinoma Multiple bone metastases of unknown primary | Not Applicable (NA) | NA | Anti-EBNA: 0,41 Anti-VCA: 4,08 | < 200 | 3,47 |
HEP 10 | 63-M-France | Larynx squamous cell carcinoma | T4N2M0 | NA | Anti-EBNA:7,13 Anti-VCA: 3,73 | < 200 | 57,5 | |
HEALTHY CONTROLS | TBS 1 | 53-M-Algeria | NA | NA | NA | Anti-EBNA: 2,79 Anti-VCA: 2,46 | < 200 | 37,7 |
TBS 2 | 34-F-France | NA | NA | NA | Anti-EBNA: 0,07 Anti-VCA: 4,57 | < 200 | 3,47 | |
TBS 3 | 29-F-France | NA | NA | NA | Anti-EBNA: 5,56 Anti-VCA: 1,65 | < 200 | 79,8 | |
TBS 4 | 25-M-France | NA | NA | NA | Anti-EBNA: 0,05 Anti-VCA: 0 | < 200 | 99 | |